(Q31007513)

28 June 2017

1 reference

title

Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance (English)

1 reference

28 June 2017

Rakesh Nagilla

1 reference

28 June 2017

Kelly A Frank

series ordinal

1 reference

28 June 2017

Larry J Jolivette

series ordinal

1 reference

28 June 2017

Keith W Ward

series ordinal

1 reference

28 June 2017

publication date

26 September 2005

1 reference

Journal of Pharmacological and Toxicological Methods

28 June 2017

published in

1 reference

28 June 2017

1 reference

28 June 2017

1 reference

28 June 2017

page(s)

106-116

1 reference

An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Utility of metabolic stability screening: comparison of in vitro and in vivo clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Physiological parameters in laboratory animals and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

ADME/PK as part of a rational approach to drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Advances in drug metabolism screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Clinical biomarkers in drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Propranolol disposition in the rat: variation in hepatic extraction with unbound drug fraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Can the pharmaceutical industry reduce attrition rates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Utility of Hepatocytes in Predicting Drug Metabolism: Comparison of Hepatic Intrinsic Clearance in Rats and Humans in Vivo and in Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

The effect of anesthesia and surgery on CYP3A activity in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

Automated quantitative and qualitative analysis of metabolic stability: a process for compound selection during drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.08.005

10.1016/J.VASCN.2005.08.005

7 January 2021

Identifiers

DOI

1 reference

28 June 2017

1 reference